B1-Arg

General Information


DRACP ID  DRACP00526

Peptide Name   B1-Arg

Sequence  VKRFKKFFRKLKKRV

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  Cathelicidin-BF15 C-terminal amidated derivative B3

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=5.5 µM MTT assay 48h 1
K562 Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia Leukemia IC50=8.7 µM MTT assay 48h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  GES-1: IC50=93.3 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00526

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C97H166N30O16

Absent amino acids  ACDEGHIMNPQSTWY

Common amino acids  K

Mass  225845

Pl  12.84

Basic residues  9

Acidic residues  0

Hydrophobic residues  6

Net charge  9

Boman Index  -5612

Hydrophobicity  -108.67

Aliphatic Index  64.67

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25462264

Title  Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities

Doi 10.1016/j.ejmech.2014.10.072

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.